Outcomes Posted - 1 hour ago

$PFE $MRNA $AZN $JNJ $NRXP mRNA BAD. Beware Big pharma. Beware Bureaucrats. Save the children. 🙏 🙏 🙏 https://open.substack.com/pub/bestofdailyclout/p/pfizerfda-knew-in-early-2021-that?r=re3i2&utm_medium=ios

amberajax2point0 Posted - 4 hours ago

$JNJ finally, pricing constructive these last few days…

5RingsPatsRule Posted - 4 hours ago

$JNJ ok. enough of this nonsense, time to head back to 180.

mrmcnair91 Posted - 6 hours ago

$JNJ

OpenOutcrier Posted - 6 hours ago

$JNJ (+0.1% pre) Johnson & Johnson (JNJ) to Acquire Proteologix for $850M Cash - SI https://ooc.bz/l/33200

DonCorleone77 Posted - 6 hours ago

$JNJ Johnson & Johnson to acquire Proteologix for $850M in cash Johnson & Johnson announced that it has entered into a definitive agreement to acquire Proteologix, a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850M in cash, with potential for an additional milestone payment. Proteologix's portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis, or AD, and moderate to severe asthma, and PX130, a bispecific antibody targeting IL-13 plus IL-22, which is in preclinical development for moderate to severe AD. Since AD and asthma are both heterogeneous diseases with different disease-driving pathways in distinct patient subpopulations, targeting multiple pathways offers the potential to deliver high-bar efficacy and remission. PX128 inhibits IL-13-mediated Th2 skin inflammation, an important disease-driving pathway in AD and asthma, as well as TSLP, a mediator of tissue inflammation in AD and asthma. Like PX128, PX130 inhibits IL-13-mediated Th2 skin inflammation. PX130 also inhibits IL-22 to restore the skin barrier and prevent inflammation from environmental triggers, such as allergens. Both assets are designed for infrequent dosing intervals, which offers convenience patients prefer. Together, these pipeline additions demonstrate a strategic approach to build a portfolio of differentiated and complementary bispecifics. In addition to PX128 and PX130, the acquisition will provide J&J with other bispecific antibody programs with applications across a variety of other diseases, which further boosts the company's capabilities to create novel bispecific programs.

Stock_Titan Posted - 7 hours ago

$JNJ Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment https://www.stocktitan.net/news/JNJ/johnson-amp-johnson-to-acquire-proteologix-inc-to-lead-in-atopic-knlqy8c3ub6a.html

Aigner_Andreas Posted - 13 hours ago

TF BUY $JNJ at 152.67 : 152.33 MegaCap 28% Shp 0.6 S 4.94 N 0.8 RSI 58.62% SRSI 100% ADXR 24.59 #stocks #trading #finance #market

burningmoneyagain Posted - 13 hours ago

$JNJ Bingo.

KenFaulkenberry Posted - 17 hours ago

My Favorite Healthcare Stocks in Each Dividend Value Builder Risk/Stability Grade: Symbol - Company Name (Risk/Stability Grade) - Yield $JNJ - Johnson & Johnson (A) - 3.2% $NVS - Novartis AG (B) - 3.7% $BMY - Bristol-Myers Squibb (C) - 5.4% $WBA - Walgreens Boots Alliance (D) - 5.6% $CVS - CVS Health (D) - 4.7%

Kawasaki1 Posted - 18 hours ago

$EBS Buy Out Imminent $JNJ

UltimateTrader_22 Posted - 1 day ago

$GNPX $2.46 HOD $2.54 @Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer https://seekingalpha.com/pr/19724315-genprex-doses-first-patient-in-acclaimminus-3-clinical-study-of-reqorsa-immunogene-therapy-in?source=tweet #BreakingNews #FDA $BMY $JNJ

autzens12thman Posted - 1 day ago

$JNJ ‘all the way up’ -DJ Khalid

Stock_Titan Posted - 1 day ago

$KVUE $JNJ Kenvue Announces Pricing of Secondary Offering https://www.stocktitan.net/news/KVUE/kenvue-announces-pricing-of-secondary-9zzshqa0a7js.html

darkpoolprints Posted - 1 day ago

NOTABLE A/H DARK POOL PRINTS FROM TUESDAY MAY 14th: $V 5.5M SHARES @ 277.74 FOR $1.5 BILLION $ADBE 654.6k SHARES @ 475.95 FOR $311.6M $JNJ 1.4M SHARES @ 151.38 FOR $215.8M $CRWD 348.6k SHARES @ 329.55 FOR $115M

DonCorleone77 Posted - 1 day ago

$NBTX $JNJ Nanobiotix announces FDA issuance of Study May Proceed Letter for NBTXR3 study Nanobiotix (NBTX) announced that the FDA issued a Study May Proceed Letter for a randomized Phase 2 study evaluating NBTXR3 for the treatment of patients with stage 3, unresectable non-small cell lung cancer. An IND to support this trial was submitted by the global trial sponsor, Johnson & Johnson Enterprise Innovation Inc., a Johnson & Johnson (JNJ) company.

topstockalerts Posted - 2 days ago

$JNJ J&J scores lowest spread of year on bonds to help fund $13 billion bid for Shockwave https://www.marketwatch.com/story/j-js-13-billion-bid-for-shockwave-turns-to-wall-street-for-funding-762241b3?mod=home-page

LieutenantJoe Posted - 2 days ago

$ELTP five fucking thousand shares traded to bring it down. This is a Goldmine plain and simple. $LLY $JNJ

TalkMarkets Posted - 2 days ago

J&J: A Healthy Dose Of Income And Growth $JNJ https://talkmarkets.com/content/stocks--equities/jj-a-healthy-dose-of-income-and-growth?post=445471

burningmoneyagain Posted - 2 days ago

$JNJ 152.5C 5/24 moving quite nicely. Good luck, I expect this to keep moving with ex-date for divy coming up.

toddz Posted - 2 days ago

$JNJ what happened at 3:30 est?

LieutenantJoe Posted - 3 days ago

$MNKD $10-$15 sooner than you all think $LLY $JNJ

PrecisionSwingTrader Posted - 3 days ago

TRADE CLOSED Symbol: $MRK Type: Buy to Cover Return: + 1.68% Entry: 10/18/2022 Adjusted Short: 130.33 Cover: 128.14 Size: 6% Rationale: Closing this position largely because of how stubborn its held this upper range. I still believe the upsloping TL since mid-March will break to the downside & this could be a bigger winner -- but, I simply ran out of time on this trade as I need the capital elsewhere. $NVAX $LLY $PFE $JNJ

InvestorPlace Posted - 3 days ago

$JNJ is selling its stake in $KVUE! https://investorplace.com/2024/05/johnson-johnson-is-officially-getting-out-of-kenvue-kvue-stock/

vanguard100 Posted - 3 days ago

$JNJ watching for more upside from this level soon..

Sarge986 Posted - 3 days ago

. Microcap Focus: Sizing Up a Micro-Cap Biotech for a Speculative Play $ACIU $JNJ #MarketRecon . https://pro.thestreet.com/trade-ideas/sizing-up-a-micro-cap-biotech-for-a-speculative-play

OpenOutcrier Posted - 3 days ago

$KVUE (-0.7% pre) $JNJ J&J to exit Kenvue, a year after spinoff - Reuters https://ooc.bz/l/32857

G101SPM Posted - 3 days ago

$LEGN $45.10 +1.86. DAC (dollar average cost) $43.145 (5.10.24). EXIT $50.00. RETAIN POSITION. OVERVIEW: (1) Reports Q1 (Mar) loss of $0.16 per share, $0.03 better than consensus of ($0.19); revenues rose 158.7% year/year to $93.9 mln vs the $143.24 consensus. Cash and cash equivalents, time deposits, and short-term investments were $1.3 billion as of March 31, 2024. Key Business Developments: Legend and Johnson & Johnson ($JNJ) entered into a Master Manufacturing and Supply Services Agreement with Novartis Pharmaceuticals Corporation to supplement our existing manufacturing capabilities and increase commercial supply of CARVYKTI. (2) Confirms that the European Commission has granted approval of CARVYKTI for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent, demonstrated disease progression on the last therapy and are refractory to lenalidomide.

DonCorleone77 Posted - 3 days ago

$KVUE $JNJ Kenvue confirms launch of 182.33M secondary offering for holders Kenvue (KVUE) announced the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock. Kenvue is not selling any shares of common stock and will not receive any proceeds from the sale of the Shares in the Offering or from the debt-for-equity exchange. In connection with the Offering, Johnson & Johnson (JNJ) is expected to exchange 182,329,550 shares of Kenvue's common stock for indebtedness of Johnson & Johnson expected to be held by Goldman Sachs & Co. LLC and J.P. Morgan. Following the debt-for-equity exchange, if consummated, the Selling Shareholders intend to sell the Shares to the underwriters in the Offering. After the completion of the proposed Offering, Johnson & Johnson will no longer own any shares of Kenvue's common stock. Goldman Sachs & Co. LLC, J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the Offering.

Stock_Titan Posted - 3 days ago

$KVUE $JNJ Kenvue Announces Launch of Secondary Offering https://www.stocktitan.net/news/KVUE/kenvue-announces-launch-of-secondary-dzz0h794erxm.html